The global general anesthesia drugs market size accounted for USD 5.40 billion in 2024, grew to USD 5.60 billion in 2025 and is expected to be worth around USD 7.79 billion by 2034, registering a CAGR of 3.72% between 2024 and 2034. The North America general anesthesia drugs market size is evaluated at USD 2.00 billion in 2024 and is expected to grow at a CAGR of 3.83% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: General Anesthesia Drugs Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Drug, 2024-2034
8.1.1. Sevoflurane
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Propofol
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Dexmedetomidine
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Remifentanil
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Desflurane
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. Midazolam
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
8.1.7. Others - (Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental, Etc.)
8.1.7.1. Market Revenue and Volume Forecast (2021-2034)
9.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Route of Administration, 2024-2034
9.1.1. Intravenous
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Inhaled
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by Application, 2024-2034
10.1.1. Heart Surgeries
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Cancer
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. General Surgery
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Knee and Hip Replacements
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Volume Forecast (2021-2034)
11.1. General Anesthesia Drugs Market Revenue and Volume Forecast, by End-use, 2024-2034
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast (2021-2034)
11.1.2. Ambulatory Surgical Centers
11.1.2.1. Market Revenue and Volume Forecast (2021-2034)
11.1.3. Others
11.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1.4. Cervical
11.1.4.1. Market Revenue and Volume Forecast (2021-2034)
11.1.5. Malignant
11.1.5.1. Market Revenue and Volume Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.1.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.1.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.1.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.2.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.2.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.2.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.2.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.2.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.2.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.3.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.3.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.3.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.3.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.3.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.4.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.4.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.4.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.4.7.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.4.8.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.5.5.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug (2021-2034)
12.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2034)
12.5.6.3. Market Revenue and Volume Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Volume Forecast, by End-use (2021-2034)
13.1. Baxter International Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Aspen Pharmacare Holdings Limited
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Hikama Pharmaceuticals plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbott Laboratories
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AbbVie Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. B. Braun Melsungen AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Fresenius SE & Co. KgaA
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Hospira Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample